Sugi Predict

Sugi Predict / Targets / PDE1A

PDE1A

Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A · P54750 · PDE1A on Sugi Atlas →

48,815 patent compounds predicted against PDE1A, 29,331 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vinpocetine Vinpocetine (SCHEMBL50081) 1.00 18/20
Vinpocetine Vinpocetine (SCHEMBL160952) 1.00 18/20
Apovincamine Apovincamine (SCHEMBL194507) 0.85 18/20
SCHEMBL239181 SCHEMBL239181 0.84 18/20
SCHEMBL437205 SCHEMBL437205 0.71 18/20
SCHEMBL285263 SCHEMBL285263 0.72 16/20
SCHEMBL285264 SCHEMBL285264 0.72 16/20
SCHEMBL407938 SCHEMBL407938 0.72 16/20
SCHEMBL155132 SCHEMBL155132 0.50 14/20
SCHEMBL291618 SCHEMBL291618 0.53 12/20
SCHEMBL299992 SCHEMBL299992 0.59 11/20
Vinburnine Vinburnine (SCHEMBL456385) 0.57 11/20
SCHEMBL298932 SCHEMBL298932 0.52 11/20
Vincamine Vincamine (SCHEMBL3767) 0.51 11/20
Vincamine Vincamine (SCHEMBL147179) 0.51 11/20
SCHEMBL299743 SCHEMBL299743 0.62 10/20
SCHEMBL298595 SCHEMBL298595 0.62 10/20
SCHEMBL298757 SCHEMBL298757 0.62 10/20
SCHEMBL299367 SCHEMBL299367 0.59 10/20
SCHEMBL299935 SCHEMBL299935 0.55 10/20

Clinical trials — most relevant to PDE1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs PHASE4COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension PHASE3COMPLETED
Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm PHASE3WITHDRAWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
A Trial of Levodopa in Angelman Syndrome PHASE2/PHASE3COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) PHASE2RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals PHASE1/PHASE2COMPLETED
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension PHASE2COMPLETED
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients PHASE2COMPLETED
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial PHASE2COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients PHASE2COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children nanCOMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Endurance Performance at Altitude nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE1A binder may also engage these)

ProteinNameSimilarity
Q61481 — 1.000 Q61481 →
P14100 — 0.998 P14100 →
Q01066 — 0.998 Q01066 →
Q01061 — 0.993 Q01061 →
PDE1B Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B 0.991 landscape →
Q64395 — 0.991 Q64395 →
Q01065 — 0.991 Q01065 →
Q64338 — 0.973 Q64338 →
PDE1C Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C 0.972 landscape →
Q63421 — 0.966 Q63421 →
PDE7A High affinity 3',5'-cyclic-AMP phosphodiesterase 7A 0.954 landscape →
A7MBL8 — 0.952 A7MBL8 →
O08593 — 0.952 O08593 →
P70453 — 0.952 P70453 →
A6NI28 — 0.951 A6NI28 →
Q07722 — 0.950 Q07722 →
Q9QW07 — 0.949 Q9QW07 →
E9Q4Z2 — 0.948 E9Q4Z2 →
Q9Z2C4 — 0.947 Q9Z2C4 →
MTMR1 Phosphatidylinositol-3-phosphate phosphatase MTMR1 0.947 landscape →
Q8BWW9 — 0.947 Q8BWW9 →
PLCB1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 0.946 landscape →
B5DFQ4 — 0.946 B5DFQ4 →
Q7YQL6 — 0.945 Q7YQL6 →
O70566 — 0.945 O70566 →
Q8BPM2 — 0.945 Q8BPM2 →
PKN2 Serine/threonine-protein kinase N2 0.944 landscape →
Q5U4T3 — 0.944 Q5U4T3 →
Q9NSV4 — 0.944 Q9NSV4 →
A4IID4 — 0.943 A4IID4 →